0:00
0:00
U.S. Clinical Study Investigates Medication to Prolong Dogs' Lifespan
Loyal, a company based in San Francisco, is conducting a large-scale study to evaluate the impact of a possible longevity drug for older dogs.
A clinical trial is currently being conducted in the United States to assess a medication that might prolong the lifespan of dogs.
The research, referred to as the STAY trial, is organized by Loyal, an animal health company located in San Francisco.
This double-blind, placebo-controlled trial will involve at least one thousand senior dogs, with the company's goal of obtaining approval from the U.S. Food and Drug Administration (FDA) based on the results.
The trial builds upon successful preclinical and pilot studies.
According to Alex Robb, the medical director of Goodheart Animal Health Center in Colorado, the dogs participating in the trial will receive daily doses of the drug over four years, along with regular clinical evaluations.
Researchers will assess whether the drug has a significant effect on longevity once the study concludes.
To be eligible for the trial, dogs must be a minimum of ten years old and weigh at least fourteen pounds.
Owners must agree to have their pet’s primary care managed by a participating study clinic and commit to multiple veterinary appointments over the four years.
The first year entails six visits, followed by two visits each year in the subsequent years.
The research aims to explore factors involved in canine aging, including their higher metabolic rates compared to humans.
While veterinary advancements have enhanced healthcare for dogs, their overall lifespan has not increased as quickly as that of humans.
Loyal intends to use the data gathered to seek conditional FDA approval for the drug by the end of the year.
Recruitment for the trial is still active at various clinics nationwide.
The research, referred to as the STAY trial, is organized by Loyal, an animal health company located in San Francisco.
This double-blind, placebo-controlled trial will involve at least one thousand senior dogs, with the company's goal of obtaining approval from the U.S. Food and Drug Administration (FDA) based on the results.
The trial builds upon successful preclinical and pilot studies.
According to Alex Robb, the medical director of Goodheart Animal Health Center in Colorado, the dogs participating in the trial will receive daily doses of the drug over four years, along with regular clinical evaluations.
Researchers will assess whether the drug has a significant effect on longevity once the study concludes.
To be eligible for the trial, dogs must be a minimum of ten years old and weigh at least fourteen pounds.
Owners must agree to have their pet’s primary care managed by a participating study clinic and commit to multiple veterinary appointments over the four years.
The first year entails six visits, followed by two visits each year in the subsequent years.
The research aims to explore factors involved in canine aging, including their higher metabolic rates compared to humans.
While veterinary advancements have enhanced healthcare for dogs, their overall lifespan has not increased as quickly as that of humans.
Loyal intends to use the data gathered to seek conditional FDA approval for the drug by the end of the year.
Recruitment for the trial is still active at various clinics nationwide.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
